Literature DB >> 27166875

Predictors of survival in parotid adenocarcinoma not otherwise specified: a National Cancer Database study of 3155 patients.

Kevin Y Zhan1, Andrew T Huang1, Sobia F Khaja1, Diana Bell2, Terry A Day1.   

Abstract

BACKGROUND: Parotid adenocarcinoma not otherwise specified (PANOS) is a common parotid cancer, but studies specifically on this subject are limited.
METHODS: We conducted a retrospective review of the National Cancer Database.
RESULTS: Ten percent of all parotid cancers were PANOS (n = 3155). Median age was 67 years. Most patients were men (62.8%) with high-grade histology (67.2%). Regional metastasis was common (35.9%), whereas occult nodal metastasis (20.2% overall) was less frequent in non-high-grade lesions (8.5% vs 31.6%; p < .001). Distant metastasis was rare (7.9%). Five-year overall survival (OS) was 47%. In multivariate analysis, age, regional metastasis, distant metastasis, high-grade, and T classification were predictors of lower survival. Patients with stage III to IV disease receiving surgery and radiotherapy had a better OS than those receiving surgery alone (51% vs 41%; p < .001).
CONCLUSION: PANOS is an aggressive disease with frequent regional metastasis and low survival. Numerous variables are associated with worse survival.
© 2016 Wiley Periodicals, Inc. Head Neck 38:1208-1212, 2016. © 2016 Wiley Periodicals, Inc.

Entities:  

Keywords:  adenocarcinoma; cancer; malignancy; parotid glands; salivary gland; survival; tumor

Mesh:

Year:  2016        PMID: 27166875     DOI: 10.1002/hed.24382

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  4 in total

1.  Outcome and management of rare high-grade "salivary" adenocarcinoma: the important role of adjuvant (chemo)radiotherapy.

Authors:  Claudia Scherl; Marlen Haderlein; Abbas Agaimy; Konstantinos Mantsopoulos; Michael Koch; Maximilian Traxdorf; Rainer Fietkau; Philipp Grundtner; Heinrich Iro
Journal:  Strahlenther Onkol       Date:  2019-07-26       Impact factor: 3.621

2.  Reirradiation for Rare Head and Neck Cancers: Orbit, Auditory Organ, and Salivary Glands.

Authors:  Hideya Yamazaki; Gen Suzuki; Norihiro Aibe; Hiroya Shiomi; Ryoong-Jin Oh; Ken Yoshida; Satoaki Nakamura; Mikio Ogita
Journal:  Cureus       Date:  2022-02-28

3.  Clinico-Epidemiological Analysis of Most Prevalent Parotid Gland Carcinomas in Poland over a 20-Year Period.

Authors:  Michał Żurek; Kamil Jasak; Karolina Jaros; Piotr Daniel; Kazimierz Niemczyk; Anna Rzepakowska
Journal:  Int J Environ Res Public Health       Date:  2022-08-18       Impact factor: 4.614

4.  Tumor to Tumor Metastasis from Adenocarcinoma Not Otherwise Specified of the Parotid Gland to Uterine Leiomyoma: Presentation of a Unique Case.

Authors:  Alexandros Psarris; Nektarios Koufopoulos; Anastasios Grivas; Dimitrios C Papatheodorou; Lubna Khaldi
Journal:  Cureus       Date:  2020-01-27
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.